Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
Public ClinicalTrials.gov record NCT00711009. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects
Study identification
- NCT ID
- NCT00711009
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Abbott
- Industry
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Interventions
- lopinavir/ritonavir (LPV/r) Drug
- emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) Drug
- raltegravir (RAL) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2008
- Primary completion
- Oct 31, 2009
- Completion
- Sep 30, 2010
- Last update posted
- Feb 13, 2012
2008 – 2010
United States locations
- U.S. sites
- 14
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 8431 | Phoenix | Arizona | 85006 | — |
| Site Reference ID/Investigator# 8432 | Beverly Hills | California | 90211 | — |
| Site Reference ID/Investigator# 8394 | Atlantis | Florida | 33462 | — |
| Site Reference ID/Investigator# 8393 | Ft. Pierce | Florida | 34982 | — |
| Site Reference ID/Investigator# 8425 | Orlando | Florida | 32803 | — |
| Site Reference ID/Investigator# 8402 | Tampa | Florida | 33614 | — |
| Site Reference ID/Investigator# 8396 | Vero Beach | Florida | 32960 | — |
| Site Reference ID/Investigator# 8395 | Atlanta | Georgia | 30303 | — |
| Site Reference ID/Investigator# 8429 | Decatur | Georgia | 30033 | — |
| Site Reference ID/Investigator# 8424 | Boston | Massachusetts | 02215 | — |
| Site Reference ID/Investigator# 8426 | Charlotte | North Carolina | 28209 | — |
| Site Reference ID/Investigator# 11461 | Huntersville | North Carolina | 28078 | — |
| Site Reference ID/Investigator# 8403 | Dallas | Texas | 75246 | — |
| Site Reference ID/Investigator# 8433 | Houston | Texas | 77004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00711009, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 13, 2012 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00711009 live on ClinicalTrials.gov.